Vnitr Lek 2018, 64(1):61-64 | DOI: 10.36290/vnl.2018.009

Examination methods for coronary atherosclerosis regression with special focus on GLAGOV trial

Tomáš Kovárník1,*, Karel Kopřiva2, Jan Pudil1
1 II. interní klinika kardiologie a angiologie 1. LF UK a VFN v Praze
2 Kardiologické oddělení Nemocnice Na Homolce, Praha

Authors summarize trials assessing regression of coronary atherosclerosis. Special interest is devoted to imagine techniques. Authors describe in a detail methodology and results of GLAGOV trial.

Keywords: coronary atherosclerosis; intravascular ultrasound; regression

Received: November 17, 2017; Accepted: January 5, 2018; Published: January 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kovárník T, Kopřiva K, Pudil J. Examination methods for coronary atherosclerosis regression with special focus on GLAGOV trial. Vnitr Lek. 2018;64(1):61-64. doi: 10.36290/vnl.2018.009.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. JACC 2005; 46(7): 1225-1228. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2005.07.006>. Go to original source... Go to PubMed...
    2. Nicholls SJ, Hsu A, Wolski K et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. JACC 2010; 55(21): 2399-2407. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2010.02.026>. Go to original source... Go to PubMed...
    3. Nicholls S, Puri R, Anderson T et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016; 316(22): 2373-2384. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.16951>. Go to original source... Go to PubMed...
    4. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006; 295(13): 1556-1565. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.295.13.jpc60002>. Go to original source... Go to PubMed...
    5. Nicholls S, Ballantyne Ch, Barter P et al. Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. N Engl J Med 2011; 365(22): 2078-2087. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1110874>. Go to original source... Go to PubMed...
    6. Otagiri K, Tsutsui H, Kumazaki S et al. Early Intervention With Rosuvastatin Decreases the Lipid Components of the Plaque in Acute Coronary Syndrome. Circ J 2011; 75(3): 633-641. Go to original source... Go to PubMed...
    7. Nair A, Margolis P, Kuban B et al. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. Eurointervention 2007; 3(1): 113-120. Go to PubMed...
    8. Puri R, Libby P, Nissen SE et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovascular Imaging 2014; 15(4): 380-388. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjci/jet251>. Go to original source... Go to PubMed...
    9. Garcia-Garcia H, Gogas B, Serruys PW et al. IVUS-based imaging modalities for tissue characterization: similarities and differences. Int J Cardiovasc Imaging 2011; 27(2): 215-224. Dostupné z DOI: <http://dx.doi.org/10.1007/s10554-010-9789-7>. Go to original source... Go to PubMed...
    10. Waxman S, Ishibashi F, Caplan JD. Rationale and use of near-infrared spectroscopy for detection of lipid-rich and vulnerable plaques. J Nucl Cardiol 2007; 14(5): 719-728. Dostupné z DOI: <http://dx.doi.org/10.1016/j.nuclcard.2007.08.001>. Go to original source... Go to PubMed...
    11. Kini AS, Baber U, Kovacic JC et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). JACC 2013; 62(1): 21-29. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.03.058>. Go to original source... Go to PubMed...
    12. Tearney G, Regar E, Akasaka T et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. JACC 2012; 59(12): 1058-1072. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.09.079>. Go to original source... Go to PubMed...
    13. Hattori K, Ozaki Y, Ismail T et al. Impact of Statin Therapy on Plaque Characteristics as Assessed by Serial OCT, Grayscale and Integrated Backscatter - IVUS. JACC Cardiovasc Imaging 2012; 5(2): 169-177. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2011.11.012>. Go to original source... Go to PubMed...
    14. Kataoka Y, Andrews J, Puri R et al. Lipid lowering therapy to modify plaque microstructures. Insights from optical coherency tomography imaging. J Atheroscler Thromb 2017; 24(4): 360-372. Dostupné z DOI: <http://dx.doi.org/10.5551/jat.RV16009>. Go to original source... Go to PubMed...
    15. Ueda Y, Hiro T, Hirayama A et al. Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque - The ZIPANGU Study. Circ J 2017; 81(11): 1611-1619. Dostupné z DOI: <http://dx.doi.org/10.1253/circj.CJ-17-0193>. Go to original source... Go to PubMed...
    16. Hougaard M, Hansen HS, Thayssen P et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med 2017; 18(2): 110-117. Dostupné z DOI: <http://dx.doi.org/10.1016/j.carrev.2016.11.010>. Go to original source... Go to PubMed...
    17. Tsujita K, Sugiyama S, Sumida H et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention The Multicenter Randomized Controlled PRECISE-IVUS Trial. JACC 2015; 66(5): 495-507. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.05.065>. Go to original source... Go to PubMed...
    18. Cannon Ch, Blazing M, Giugliano R et al. for the IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>. Go to original source... Go to PubMed...
    19. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM et al. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis 2016; 248: 117-122. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.03.010>. Go to original source... Go to PubMed...
    20. Puri R, Nissen SE, Ballantyne Ch et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J 2013; 34(24): 1818-1825. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht084>. Go to original source... Go to PubMed...
    21. Hwang DS, Shin ES, Kim SJ et al. Early Differential Changes in Coronary Plaque Composition According to Plaque Stability Following Statin Initiation in Acute Coronary Syndrome: Classification and Analysis by Intravascular Ultrasound-Virtual Histology. Yonsei Med J 2013; 54(2): 336-344. Dostupné z DOI: <http://dx.doi.org/10.3349/ymj.2013.54.2.336>. Go to original source... Go to PubMed...
    22. Stegman B, Shao M, Nicholls SJ et al. Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. Atherosclerosis 2016; 254: 78-84. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.09.059>. Go to original source... Go to PubMed...
    23. Sabatine M, Giugliano R, Keech A et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18): 1713-1722. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>. Go to original source... Go to PubMed...
    24. Thondapu V, Bourantas Ch, Foin N et al. Biomechanical stress in coronary atherosclerosis: emerging insights from computational modeling. Eur Heart J 2017; 38(2): 81-92. Dostupné z DOI: <https://doi.org/10.1093/eurheartj/ehv689>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.